SRTA

#2917
Strata Critical Medical, Inc. - Class A Common Stock
5.6 6 USD
-0.05%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
5.66
5.66
Intervallo Annuale
3.85
6.50
Variazione giornaliera
-5.19%
Variazione Mensile
+12.08%
Variazione di 6 mesi
+34.76%
Variazione Annuale
+31.02%
Chiusura Precedente
5.9 7
Open
5.6 6
Minimo
5.6 6
Massimo
5.6 6
Volume
102
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Strata Critical Medical, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Strata Critical Medical, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Strata Critical Medical, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Strata Critical Medical, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Strata Critical Medical, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Strata Critical Medical, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Strata Critical Medical, Inc. current report, Q1 FY2026
8-K

2025

Annual report, FY2025
Strata Critical Medical, Inc. annual report, FY2025
10-K
Current report, Q4 FY2025
Strata Critical Medical, Inc. current report, Q4 FY2025
8-K
Current report, Q4 FY2025
Strata Critical Medical, Inc. current report, Q4 FY2025
8-K

Strata Critical Medical, Inc. current report, Q3 FY2021

Full document

Business Context and Reporting Period

This Form 8-K is a current report filed by Blade Air Mobility, Inc. (not Strata Critical Medical, Inc.) on September 22, 2021. The filing addresses corporate governance changes, specifically the appointment of a new independent director and the resignation of an existing director.

Key Financial Metrics

The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. This report focuses exclusively on personnel changes and director compensation policies.

Material Changes

  • Board Resignation: David Zaslav resigned from the Board of Directors effective September 22, 2021. The resignation was not the result of any disagreement with the Company.
  • Board Appointment: Reginald Love was appointed as an independent director, effective September 22, 2021, replacing Mr. Zaslav as a Class I director.
  • Committee Assignment: Mr. Love was appointed to the Nominating and Corporate Governance Committee.

Guidance, Outlook, and Compensation

The filing details the Company's compensation program for non-employee directors:

  • Base Compensation: Annual awards with a grant date value of $150,000, payable in equity, cash, or flight service credits (or a combination).
  • Vesting: Awards generally vest over 12 months on a quarterly basis.
  • Committee Chair Fees: Additional $25,000 for chairs of the Audit, Compensation, and Nominating/Corporate Governance Committees.
  • Independent Chair Fee: Additional $50,000 for the independent chair of the Board.
  • Future Review: The Company intends to review its non-employee director compensation program in the near term.

Investor Verification Checklist

  • Verify the effective date of Reginald Love's appointment and David Zaslav's resignation (September 22, 2021).
  • Confirm the composition of the Board following the transition of the Class I director seat.
  • Review the specific mix of equity, cash, and flight service credits in the $150,000 director compensation package.
  • Monitor future filings for the anticipated review of the director compensation program.